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Background: Myocardial blush grade (MBG) predicts mortality after reperfusion of ST-segment elevation myocardial infarction patients even 
among those achieving normal epicardial reperfusion. Whether MBG is useful in predicting outcomes in non-ST segment elevation (NSTEMI) patients 
after early invasive management is unknown.
Methods: The ACUITY trial randomized 13,819 pts with moderate and high risk ACS to unfractionated heparin or enoxaparin + glycoprotein IIb/IIIa 
inhibitor (GPI), vs bivalirudin + GPI, vs bivalirudin alone. The angiographic substudy of ACUITY comprised 7000 patients. We examined the short and 
long term outcomes of patients according to MBG (MBG 0/1 vs MBG 2 vs MBG 3).
Results: MBG was analyzable in 3115 of 3826 patients (81.4%) in whom PCI was performed. Patients with MBG 0/1 had increased rates of 
30-day net adverse clinical events (NACE; composite ischemia or non-CABG major bleeding) and composite ischemia (death, MI or unplanned 
revascularization) driven by increased unplanned revascularization rates (Table). Furthermore, among 3123 patients with post-procedural TIMI-3 
flow, those with MBG 0/1 had higher rates of 30-day unplanned revascularization (Table). By 1-year, outcomes did not differ according to post PCI 
MBG. Multivariable analysis will be presented.
Conclusions: MBG is a useful angiographic parameter in providing prognostic information in NSTEMI patients at 30 days. However, unlike in 
STEMI, these data do not support a prognostic role at 1 year for MBG in NSTEACS. 
30-day outcomes MBG 0/1 MBG 2 MBG 3 P-Value
Overall Population n=84 n=370 n=2661
NACE 25.1% 10.3% 14.4% 0.0009
Composite ischemia 19.1% 7.3% 9.7% 0.002
Death 2.4% 0.3% 0.8% 0.13
MI 12.1% 5.1% 7.6% 0.06
Unplanned revascularization 10.9% 2.5% 3.3% 0.0002
Final TIMI-3 Patients n=521 n=523 n=2077
NACE 13.9% 11.5% 14.3% 0.29
Composite Ischemia 13.0% 6.2% 9.6% 0.10
Death 0.0% 0.3% 0.8% 0.50
MI 6.6% 4.1% 7.4% 0.09
Unplanned revascularization 13.0% 2.4% 3.3% 0.004
